ArriVent BioPharma, Inc. (AVBP) stock
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.69−0.87 (-7.53%)
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
Earnings
ArriVent BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$5.00M
EPS, Q3 FY2026
-$0.81
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of ArriVent BioPharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026after the close | $5.00M | – | -$0.81 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026after the close | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
ArriVent BioPharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When ArriVent BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases ArriVent BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- News
- News
- Update
See a number that looks wrong?